Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant

Vaccine

Volumn 31, Issue 3, 2013, Pages 472-479

  Sun, Jing ^a   Hou, Jue ^b   Li, Dingfeng ^b   Liu, Yong ^b   Hu, Ningzhu ^a   Hao, Yanling ^b   Fu, Jingjing ^b   Hu, Yunzhang ^a   Shao, Yiming ^b  

^a INSTITUTE OF MEDICAL BIOLOGY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Adjuvant; BCG PSN; HIV 1 DNA vaccine

Indexed keywords

BACILLUS CALMETTE GUERIN POLYSACCHARIDE NUCLEIC ACID FRACTION; DNA VACCINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE MODEL; DNA IMMUNIZATION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL; TH1 CELL; VIRUS IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; CHINA; FEMALE; HIV ANTIBODIES; HIV-1; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA;

EID: 84871665907     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.024     Document Type: Article

References (52)

1. Tang D.C., DeVit M., Johnston S.A. Genegic immunization is a simple method for eliciting an immune response. Nature 1992, 356:152-154.
2. Yankauckas M.A., Morrow J.E., Parker S.E., Abai A., Rhodes G.H., Dwarki V.J., et al. Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene. DNA Cell Biol 1993, 12(9):771-776.
3. Graham B.S., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1DNA candidate vaccine. J Infect Dis 2006, 194(12):1650-1660.
4. Manoj S., Babiuk L.A., Van Drunen Littel-Van Den Hurk S. Approaches to enhance the efficacy of DNA vaccines. Crit Rev Clin Lab Sci 2004, 41(1):1-39.
5. Sun J., Li D., Hao Y., Zhang Y., Fan W., Fu J., et al. Posttranscriptional regulatory elements enhance antigen expression and DNA vaccine efficacy. DNA Cell Biol 2009, 28(5):233-240.
6. Mbow M.L., De Gregorio E., Valiante N.M., Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol 2010, 22(3):411-416.
7. O'Hagan D.T., De Gregorio E. The path to a successful vaccine adjuvant - 'the long and winding road'. Drug Discov Today 2009, 14(11-12):541-551.
8. Azuma I., Ribi E.E., Meyer T.J., Zbar B. Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. J Natl Cancer Inst 1974, 52:95-101.
9. Besra G.S., Chatterjee D. Lipids and carbohydrates of Mycobacterium tuberculosis. Tuberculosis: pathogenesis, protection, and control 1994, 285-306. American Society for Microbiology, Washington, D.C. B.R. Bloom (Ed.).
10. Brennan P.J., Draper P. Ultrastructure of Mycobacterium tuberculosis. Tuberculosis: pathogenesis, protection, and control 1994, 271-284. American Society for Microbiology, Washington, D.C. B.R. Bloom (Ed.).
11. Tsuji S., Matsumoto M., Takeuchi O., Akira S., Azuma I., Hayashi A., et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin: involvement of Toll-like receptors. Infect Immun 2000, 68(12):6883-6890.
12. Lee K.W., Jung J., Lee Y., Kim T.Y., Choi S.Y., Park J., et al. Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA. Mol Immunol 2006, 43(13):2107-2118.
13. Krieg A.M. GpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20(1):709-760.
14. ® HBV vaccine adjuvant. Vaccine 2012, 30(32):4719-4727.
15. Li D., Liu Y., Zhang Y., Xu J., Hong K., Sun M., et al. Adjuvant effects of plasmid-generated hairpin RNA molecules on DNA vaccination. Vaccine 2007, 25(39-40):6992-7000.
16. Feltquate D.M., Heaney S., Webster R.G., Robinson H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 1997, 158(5):2278-2284.
17. McCluskie M.J., Brazolot Millan C.L., Gramzinski R.A., Robinson H.L., Santoro J.C., Fuller J.T., et al. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med 1999, 5(5):287-300.
18. Oliveira S.C., Rosinha G.M., de-Brito C.F., Fonseca C.T., Afonso R.R., Costa M.C. Immunological properties of gene vaccines delivered by different routes. Braz J Med Biol Res 1999, 32(2):207-214.
19. Deng Y., Chen Y., Chen X., Li Y., Zhou L. A comparative study on the effect of BCG-PSN and thymopeptides on T-lymphocyte subsets of normal and immunosuppressed mice. J Huazhong Univ Sci Technolog Med Sci 2003, 23(4):339-343.
20. Greenland John R., Letvin Norman L. Chemical adjuvants for plasmid DNA vaccines. Vaccine 2007, 25(19):3731-3741.
21. Buonaguro F.M., Tornesello M.L., Buonaguro L. New adjuvants in evolving vaccine strategies. Expert Opin Biol Ther 2011, 11(7):827-832.
22. Park B.S., Song D.H., Kim H.M., et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009, 458(7242):1191-1195.
23. Buonaguro L., Tornesello M.L., Tagliamonte M., Gallo R.C., Wang L.X., Kamin-Lewis R., et al. Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J Virol 2006, 80:9134-9143.
24. Jahrsdorfer B., Weiner G.J. CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther 2008, 3:27-32.
25. Vollmer J., Weeratna R., Payette P., Jurk M., Schetter C., Laucht M., et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004, 34:251-262.
26. Audibert F.M., Lise L.D. Adjuvants: current status, clinical perspectives and future prospects. Immunol Today 1993, 14:281-284.
27. Uehori J., Matsumoto M., Tsuji S., Akazawa T., Takeuchi O., Akira S., et al. Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin peptidoglycan. Infect Immun 2003, 71(8):4238-4249.
28. Medzhitov R., Janeway C.A. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997, 91:295-298.
29. Aliprantis A.O., Yang R.B., Mark M.R., Suggett S., Devaux B., Radolf J.D., et al. Cell activation andapoptosis by bacterial lipoproteins through Toll-like receptor-2. Science 1999, 285:736-739.
30. Brightbill H.D., Libraty D.H., Krutzik S.R., Yang R.B., Belisle J.T., Bleharski J.R., et al. Host defense mechanisms triggered by microbial lipoproteins through Toll-like receptors. Science 1999, 285:732-736.
31. Means T.K., Lien E., Yoshimura A., Wang S., Golenbock D.T., Fenton M.J. The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J Immunol 1999, 163:6748-6755.
32. Means T.K., Wang S., Lien E., Yoshimura A., Golenbock D.T., Fenton M.J. Human Toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol 1999, 163:3920-3927.
33. Schwandner R., Dziarski R., Wesche H., Rothe M., Kirschning C.J. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2. J Biol Chem 1999, 274:17406-17409.
34. Takeuchi O., Hoshino K., Kawai T., Sanjo H., Takada H., Ogawa T., et al. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 1999, 11:443-451.
35. Yoshimura A., Lien E., Ingalls R.R., Tuomanen E., Dziarski R., Golenbock D. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 1999, 163:1-5.
36. Zhu X., Ramos T.V., Gras-Masse H., Kaplan B.E., BenMohamed L. Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur J Immunol 2004, 34(11):3102-3114.
37. Hosmalin A., Andrieu M., Loing E., Desoutter J.F., Hanau D., Gras-Masse H., et al. Lipopeptide presentation pathway in dendritic cells. Immunol Lett 2001, 79(1-2):97-100.
38. BenMohamed L., Gras-Masse H., Tartar A., Daubersies P., Brahimi K., Bossus M., et al. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur J Immunol 1997, 27(5):1242-1253.
39. Daubersies P., Thomas A.W., Millet P., Brahimi K., Langermans J.A., Ollomo B., et al. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med 2000, 6(11):1258-1263.
40. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124(4):783-801.
41. Kumar H., Kawai T., Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun 2009, 388(4):621-625.
42. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
43. Takeshita F., Leifer C.A., Gursel I., Ishii K., Takeshita S., Gursel M., et al. Cutting Edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 2001, 167(7):3555-3558.
44. Bauer S., Kirschning C.J., Hacker H., Redecke V., Hausmann S., Akira S., et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001, 98(16):9237-9242.
45. Bauer M., Heeg K., Wagner H., Lipford G.B. DNA activates human immune cells through a CpG sequence-dependent manner. Immunology 1999, 97(4):699-705.
46. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760.
47. Klinman D.M., Yi A., Beaucage S.L., Conover J., Krieg A.M. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFNg. Proc Natl Acad Sci USA 1996, 93:2879-2883.
48. Ballas Z.K., Rasmussen W.L., Krieg A.M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996, 157:1840-1845.
49. Halpern M.D., Kurlander R.J., Pisetsky D.S. Bacterial DNA induces murine interferon-gamma production by stimulation of IL-12 and tumor necrosis factor-alpha. Cell Immunol 1996, 167:72-78.
50. Jiao X., Lo-Man R., Guermonprez P., Fiette L., Dériaud E., Burgaud S., et al. Dendritic cells are host cells for mycobacteria in vivo that trigger innate and acquired immunity. J Immunol 2002, 168(3):1294-1301.
51. Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004, 82(5):488-496.
52. Zuo C.X., Huang J.H., Liao Z.H., Lu J.Y., Chen J. Effects of BCG-PSN on serum levels of IL-4 and IL-12 in patients with condyloma acuminatum. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2004, 29(6):690-692.